On September 12, 2023 Traverse Biotech, a US-based biotechnology company focused on the development of immunotherapies from international biopharma companies, reported that it has signed a license agreement with Genmab under which Traverse will develop and commercialize a bispecific antibody for cancer immunotherapy (Press release, Traverse Biotech, SEP 12, 2023, View Source [SID1234635118]). This next-generation antibody was created using Genmab’s proprietary DuoBody bispecific antibody technology platform as a targeted treatment candidate for cancers expressing an undisclosed tumor-associated antigen. Targeting this tumor-associated antigen with the bispecific antibody will direct T cell-mediated cytotoxicity against both solid and liquid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the license agreement, Traverse will use its operational and development expertise to advance and commercialize the bispecific antibody program. This license agreement is expected to bring a much-needed novel oncology product to patients. The aim of the license agreement is to leverage DuoBody, a proven technology and the basis of four FDA-approved bispecific medicines and develop and commercialize a novel immuno-oncology product.

"We are highly motivated to work with a product candidate derived from Genmab’s state-of-the-art bispecific technology," said Brandy Houser, Ph.D., CEO of Traverse Biotech. "By focusing our energy on developing assets from clinically validated technologies, we can accelerate development and ultimately improve the treatment landscape for patients battling cancer," said Bill Polvino, M.D., Executive Chairman.